11 Mar 2015 Posted in News By Press Office
This announcement is another advancement in medical innovation in the UK and signals the potential for the UK to better serve patients through new approaches in the development and targeting of medicines.
Commenting on the announcement ABPI Executive Director Research Medical and Innovation Dr Virginia Acha said:
“This announcement demonstrates that in the UK, we are moving from policy to practice in our strategies to improve access for patients to new and targeted therapies.
"Breakthroughs in genomic science, such as those announced today, and continued investment in technology, show that the potential is there for the UK to lead in the implementation of precision medicine and the next generation of healthcare innovation globally."
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811